Action REGN34 REGENERON PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Regeneron Pharmaceuticals, Inc. Sao Paulo

Actions

REGN34

BRREGNBDR005

Temps Différé Sao Paulo
Autres places de cotation
 18:13:02 05/07/2024 		Varia. 5j. Varia. 1 janv.
94,76 BRL +20,88 % Graphique intraday de Regeneron Pharmaceuticals, Inc. -2,32 % +39,13 %
03/07 Regeneron et Sanofi annoncent l'approbation européenne d'un traitement contre la broncho-pneumopathie chronique obstructive MT
03/07 Nouvelle indication pour le Dupixent de Sanofi en Europe AW

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Sanofi - Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
AQ
REGENERON PHARMACEUTICALS, INC. - DUPIXENT APPROVED IN THE EUROPEAN UNION AS THE FIRST-EVER TARGETED THERAPY FOR PATIENTS WITH COPD
AQ
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
GL
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
AQ
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
REGENERON - ODRONEXTAMAB RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA
AQ
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
GL
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
GL
Sanofi - Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
AQ
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
GL
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
AQ
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
GL
Sanofi - Dupixent recommended for EU approval by the CHMP to treat patients with COPD
AQ
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GL
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action REGN
  4. Action REGN34
  5. Actualités Regeneron Pharmaceuticals, Inc.
  6. Communiqués